(LMAT) LeMaitre Vascular - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 2.243m USD | Total Return: 18.1% in 12m

Vascular Grafts, Catheters, Biologic Patches, Valvulotomes, Shunts
Total Rating 63
Safety 80
Buy Signal 0.34
Medical Instruments & Supplies
Industry Rotation: +1.6
Market Cap: 2.24B
Avg Turnover: 25.7M
Risk 3d forecast
Volatility33.8%
VaR 5th Pctl5.66%
VaR vs Median1.76%
Reward TTM
Sharpe Ratio0.55
Rel. Str. IBD60.5
Rel. Str. Peer Group74.4
Character TTM
Beta0.595
Beta Downside0.703
Hurst Exponent0.403
Drawdowns 3y
Max DD33.32%
CAGR/Max DD0.56
CAGR/Mean DD1.52
EPS (Earnings per Share) EPS (Earnings per Share) of LMAT over the last years for every Quarter: "2021-03": 0.28, "2021-06": 0.4, "2021-09": 0.3, "2021-12": 0.28, "2022-03": 0.27, "2022-06": 0.16, "2022-09": 0.25, "2022-12": 0.25, "2023-03": 0.27, "2023-06": 0.36, "2023-09": 0.33, "2023-12": 0.38, "2024-03": 0.44, "2024-06": 0.52, "2024-09": 0.49, "2024-12": 0.49, "2025-03": 0.48, "2025-06": 0.6, "2025-09": 0.62, "2025-12": 0.68, "2026-03": 0.68,
EPS CAGR: 47.09%
EPS Trend: 95.6%
Last SUE: 2.56
Qual. Beats: 1
Revenue Revenue of LMAT over the last years for every Quarter: 2021-03: 35.883, 2021-06: 40.67, 2021-09: 38.368, 2021-12: 39.503, 2022-03: 39.561, 2022-06: 42.108, 2022-09: 39.028, 2022-12: 40.954, 2023-03: 47.075, 2023-06: 50.115, 2023-09: 47.411, 2023-12: 48.883, 2024-03: 53.478, 2024-06: 55.849, 2024-09: 54.819, 2024-12: 55.717, 2025-03: 59.871, 2025-06: 64.232, 2025-09: 61.046, 2025-12: 64.453, 2026-03: 66.551,
Rev. CAGR: 12.98%
Rev. Trend: 96.4%
Last SUE: -0.11
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

Confidence

Description: LMAT LeMaitre Vascular

LeMaitre Vascular, Inc. specializes in the development and distribution of medical devices and implants tailored for vascular surgery. Its product portfolio includes human tissue allografts, biologic patches derived from bovine materials, and specialized catheters for clot removal and blood flow occlusion. The company also provides surgical tools such as valvulotomes and titanium clip closure systems, serving markets across the Americas, Europe, and the Asia Pacific.

The vascular surgery sector is characterized by high barriers to entry due to stringent regulatory approval processes for biologic implants and human tissue processing. LeMaitre utilizes a hybrid business model, leveraging a direct sales force in major markets while employing distributors to reach smaller international territories. This niche focus allows the company to compete by providing specialized instruments that larger, diversified med-tech firms may overlook.

For a deeper look into the companys historical performance and valuation metrics, consider reviewing the data on ValueRay.

Headlines to Watch Out For
  • Higher average selling prices for biologic patches and allografts drive margin expansion
  • Expanding direct sales force in international markets accelerates organic revenue growth
  • Strategic acquisitions of niche vascular devices provide inorganic earnings diversification
  • Regulatory approval timelines for new cryopreserved tissue products impact market entry
  • Shift toward minimally invasive procedures creates competitive pressure on traditional surgical tools
Piotroski VR‑10 (Strict) 6.5
Net Income: 62.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA 5.17 > 1.0
NWC/Revenue: 173.4% < 20% (prev 169.4%; Δ 3.98% < -1%)
CFO/TA 0.14 > 3% & CFO 87.3m > Net Income 62.4m
Net Debt (-177.4m) to EBITDA (90.5m): -1.96 < 3
Current Ratio: 14.32 > 1.5 & < 3
Outstanding Shares: last quarter (23.0m) vs 12m ago 0.58% < -2%
Gross Margin: 72.39% > 18% (prev 0.69%; Δ 7.17k% > 0.5%)
Asset Turnover: 43.23% > 50% (prev 40.69%; Δ 2.54% > 0%)
Interest Coverage Ratio: 12.48 > 6 (EBITDA TTM 90.5m / Interest Expense TTM 5.19m)
Altman Z'' 7.27
A: 0.71 (Total Current Assets 477.8m - Total Current Liabilities 33.4m) / Total Assets 629.5m
B: 0.31 (Retained Earnings 194.7m / Total Assets 629.5m)
C: 0.11 (EBIT TTM 64.8m / Avg Total Assets 592.8m)
D: 0.86 (Book Value of Equity 191.1m / Total Liabilities 222.9m)
Altman-Z'' Score: 7.27 = AAA
Beneish M -3.18
DSRI: 0.90 (Receivables 35.8m/35.1m, Revenue 256.3m/226.3m)
GMI: 0.95 (GM 72.39% / 68.80%)
AQI: 0.86 (AQ_t 0.16 / AQ_t-1 0.19)
SGI: 1.13 (Revenue 256.3m / 226.3m)
TATA: -0.04 (NI 62.4m - CFO 87.3m) / TA 629.5m)
Beneish M-Score: -3.18 (Cap -4..+1) = AA
What is the price of LMAT shares? As of May 19, 2026, the stock is trading at USD 100.83 with a total of 478,607 shares traded.
Over the past week, the price has changed by -0.80%, over one month by -12.32%, over three months by +11.54% and over the past year by +18.09%.
Is LMAT a buy, sell or hold? LeMaitre Vascular has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold LMAT.
  • StrongBuy: 3
  • Buy: 2
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the LMAT price?
Analysts Target Price 120.1 19.1%
LeMaitre Vascular (LMAT) - Fundamental Data Overview as of 15 May 2026
P/E Trailing = 36.0919
P/E Forward = 36.9004
P/S = 8.7531
P/B = 6.0765
P/EG = 3.0701
Revenue TTM = 256.3m USD
EBIT TTM = 64.8m USD
EBITDA TTM = 90.5m USD
Long Term Debt = 168.9m USD (from longTermDebt, last quarter)
Short Term Debt = 3.45m USD (from shortTermDebt, last quarter)
Debt = 189.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -177.4m USD (recalculated: Debt 189.8m - CCE 367.2m)
Enterprise Value = 2.07b USD (2.24b + Debt 189.8m - CCE 367.2m)
Interest Coverage Ratio = 12.48 (Ebit TTM 64.8m / Interest Expense TTM 5.19m)
EV/FCF = 26.11x (Enterprise Value 2.07b / FCF TTM 79.1m)
FCF Yield = 3.83% (FCF TTM 79.1m / Enterprise Value 2.07b)
FCF Margin = 30.87% (FCF TTM 79.1m / Revenue TTM 256.3m)
Net Margin = 24.35% (Net Income TTM 62.4m / Revenue TTM 256.3m)
Gross Margin = 72.39% ((Revenue TTM 256.3m - Cost of Revenue TTM 70.8m) / Revenue TTM)
Gross Margin QoQ = 72.72% (prev 71.66%)
Tobins Q-Ratio = 3.28 (Enterprise Value 2.07b / Total Assets 629.5m)
Interest Expense / Debt = 0.68% (Interest Expense 1.30m / Debt 189.8m)
Taxrate = 20.30% (3.99m / 19.7m)
NOPAT = 51.7m (EBIT 64.8m * (1 - 20.30%))
Current Ratio = 14.32 (Total Current Assets 477.8m / Total Current Liabilities 33.4m)
Debt / Equity = 0.47 (Debt 189.8m / totalStockholderEquity, last quarter 406.6m)
Debt / EBITDA = -1.96 (Net Debt -177.4m / EBITDA 90.5m)
Debt / FCF = -2.24 (Net Debt -177.4m / FCF TTM 79.1m)
Total Stockholder Equity = 385.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.53% (Net Income 62.4m / Total Assets 629.5m)
RoE = 16.19% (Net Income TTM 62.4m / Total Stockholder Equity 385.4m)
RoCE = 11.70% (EBIT 64.8m / Capital Employed (Equity 385.4m + L.T.Debt 168.9m))
RoIC = 9.33% (NOPAT 51.7m / Invested Capital 554.0m)
WACC = 7.49% (E(2.24b)/V(2.43b) * Re(8.08%) + D(189.8m)/V(2.43b) * Rd(0.68%) * (1-Tc(0.20)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.41 | Cagr: 1.12%
[DCF] Terminal Value 83.27% ; FCFF base≈63.9m ; Y1≈78.9m ; Y5≈134.5m
[DCF] Fair Price = 120.7 (EV 2.58b - Net Debt -177.4m = Equity 2.76b / Shares 22.9m; r=7.49% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 95.61 | EPS CAGR: 47.09% | SUE: 2.56 | # QB: 1
Revenue Correlation: 96.45 | Revenue CAGR: 12.98% | SUE: -0.11 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.81 | Chg30d=+6.61% | Revisions=+50% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.73 | Chg30d=+1.04% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=2.99 | Chg30d=+3.01% | Revisions=+50% | GrowthEPS=+18.6% | GrowthRev=+12.1%
EPS next Year (2027-12-31): EPS=3.26 | Chg30d=+2.44% | Revisions=+56% | GrowthEPS=+9.1% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: +56%